Clinical Trials Logo

Pentoxifylline clinical trials

View clinical trials related to Pentoxifylline.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT02951299 Not yet recruiting - Acute Kidney Injury Clinical Trials

The Protective Effect of Pentoxifylline on Acute Kidney Injury

Start date: May 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Acute kidney injury (AKI) has a frequency of 7.0 % in hospital inpatients and is especially common in critically ill patients, in whom the prevalence of acute kidney injury is greater than 40% at admission to the intensive care unit if sepsis is present. Therefore, alternative strategies are required to confer better or more complete renoprotection for those who suffered from AKI. There had been many studies demonstrated that the phosphodiesterase inhibitor pentoxifylline (PTX) is a potent anti-inflammatory, anti-proliferative, and anti-fibrotic agent capable of attenuating experimental renal disease such as drugs, ischemic and sepsis induced AKI. We thereby design this controlled, non-randomized clinical trial, aiming at investigating the potential renoprotective efficacy of PTX, as compared to placebo, in 200 patients with AKI.